At a glance
ClinicalIndex Comparison RecordN/ACompleted· 986 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-center, Retrospective Study to Evaluate the Clinical Performance of Artificial Intelligence Medical Assisted Diagnostic Software (VeriSee AMD) for Screening of Age-Related Macular Degeneration
In Brief
An observational study for Macular Degeneration, Age Related and Maculopathy, Age Related. Completed, enrolled 986 participants across 1 site.
Detailed Summary
An observational study is designed to evaluate the clinical performance of VeriSee AMD for potential age-related macular degeneration (AMD) screening from color fundus photography images. The sensitivity and specificity of VeriSee AMD's automated image analysis for screening AMD will be determined through the comparison with the gold standard, which is the judgment of AMD by the ophthalmologists.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesTaiwan
CollaboratorsNational Taiwan University Hospital
Timeline
N/ACompletedFinished
20222023202420252026
Enrollment StartJan 2022
Primary CompletionMar 2022
Study CompletionAug 2022
First PostedOct 2022
TodayJul 2026
First PostedOct 26, 2022
Enrollment StartJan 17, 2022
Primary CompletionMar 3, 2022
Study CompletionAug 10, 2022
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 3.7 years ago